Pharmacology
DrugBankDescription
25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist. It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion . It was discovered in 2014 at the University of Copenhagen.
Mechanism of Action
25CN-NBOH is one of the most selective agonist ligands for the 5-HT2A receptor discovered. It has a pKi of 8.88 at the human 5-HT2A receptor and is 100x more selective for 5-HT2A over 5-HT2C, and 46x more selective for 5-HT2A over 5-HT2B .
Effect Profile
CuratedStrong body load with moderate visuals, mild headspace and auditory effects
Tolerance & Pharmacokinetics
drugs.wikiCross-Tolerances
Harm Reduction
drugs.wiki• Misrepresentation: NBOH/NBOMe blotters have repeatedly been sold as LSD; microgram doses plus uneven laying raise overdose risk. Do not assume unknown blotter is LSD; use reagents and drug checking when available. • Testing: Use indole‑detecting reagents (Ehrlich or Hofmann) to confirm lysergamide; Marquis does not react with LSD but can show reactions with many NBOMe/NBOH—use both types to discriminate. UV fluorescence can help (LSD fluoresces; NBOMe/NBOH often do not). • Oral ‘inactivity’ myth: Swallowing NBOH/NBOMe is not a reliable way to avoid effects; oral activity is variable. Treat any unknown blotter as potentially active when swallowed. • Volumetric dosing: Never eyeball powder or highly concentrated solutions. For any handling beyond pre‑laid blotters, pre‑dilute to a known µg/mL and measure by volume; avoid powder insufflation because typical milligram scales cannot resolve safe microgram doses. • Intranasal caution: Faster onset but more adverse effects; cluster reports with 25B‑NBOH include status epilepticus following insufflation. Prefer transmucosal over intranasal and avoid powders. • Cardiovascular strain: Vasoconstriction and tachycardia are common; combining with stimulants or vasoconstrictive decongestants increases risk. Screen for personal/family cardiovascular disease and hydrate, keep cool, and avoid redosing. • Lithium: Psychedelics plus lithium have repeatedly been linked to seizures and medical emergencies; avoid entirely. • Tramadol: Lowers seizure threshold and has produced seizures in combinations with other psychoactives; avoid. • Synergy with LSD/other psychedelics: Users report extreme potentiation; do not combine on a first exposure. Cross‑tolerance can still leave side‑effect risk at similar doses. • HPPD risk: NBOMe/NBOH use is anecdotally associated with a relatively higher incidence of lingering visual phenomena; minimize frequency, dose, and avoid sleep deprivation. • Storage/handling: Protect blotters/solutions from heat and light; label clearly to prevent accidental ingestion by others. Case anecdotes describe severe outcomes after accidental dosing from mislabeled bottles.
References
Drugs.wiki References
- TripSit Wiki – NBOMes overview (dosing, duration, HR)
- Bluelight safety sticky – NBOMe misrepresentation/testing & oral myth caution
- ReagentTesting subreddit – LSD vs NBOMe reagent advice (Ehrlich/Hoffmann vs Marquis)
- Bluelight – The Main LSD & Lithium Thread (seizure/ER risk)
- Bluelight – LSD and 25I‑NBOMe synergy caution
- Bluelight – 25B‑NBOH poisonings cluster (PubMed link inside)
- TripSit combinations wiki – tramadol lowers seizure threshold; general combinations risk framework
- Bluelight – 25I‑NBOH thread (tolerance discussion)